Archaea from the gut microbiota of humans: Could be linked to chronic diseases?. (October 2022)

• Record Type: Journal Article
• Authors: Mafra, Denise; Ribeiro, Marcia; Fonseca, Larissa; Regis, Bruna; Cardozo, Ludmila F.M.F.; Fragoso dos Santos, Henrique; Emiliano de Jesus, Hugo; Schultz, Junia; Shiels, Paul G.; Stenvinkel, Peter; Rosado, Alexandre
• Is Part Of: Anaerobe. Volume 77(2022)
• Publication Date: 2022-10
• Subjects: Archaea -- Gut microbiota -- Methane -- Chronic kidney disease -- Cardiovascular disease; Anaerobic infections -- Periodicals; Anaerobic bacteria -- Periodicals; Bacterial diseases -- Periodicals; Computer network resources; Anaerobic protozoa -- Periodicals; 579.3
• DOI: 10.1016/j.anaerobe.2022.102629
• Languages: English
• ISSNs: 1075-9964

Abstract

Abstract: Archaea comprise a unique domain of organisms with distinct biochemical and genetic differences from bacteria. Methane-forming archaea, methanogens, constitute the predominant group of archaea in the human gut microbiota, with Methanobrevibacter smithii being the most prevalent. However, the effect of methanogenic archaea and their methane production on chronic disease remains controversial. As perturbation of the microbiota is a feature of chronic conditions, such as cardiovascular disease, neurodegenerative diseases and chronic kidney disease, assessing the influence of archaea could provide a new clue to mitigating adverse effects associated with dysbiosis. In this review, we will discuss the putative role of archaea in the gut microbiota in humans and the possible link to chronic diseases. Highlights: In humans, the predominant Archaea are methanogens in the gastrointestinal system. Archaea may reduce ROS and TMAO production and intestinal permeability. Methane can indirectly act in a mechanism that regulates the antioxidant response.